drug

PER-001

Phase 2updated 3mo ago

by Perfuse Therapeutics Inc

Phase 2

community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying PER-001

phase2A Study of PER-001 in Participants With Diabetic Retinopathycompletedn=27
phase2A Study of PER-001 in Participants With Open-Angle Glaucomaactive not recruitingn=36

News(1)

Bayer to buy Perfuse for up to $2.45B, bolstering eye drug pipeline
Centered around a glaucoma therapy in mid-stage testing, the deal is Bayer’s first drug company acquisition in several years and potentially its largest since it purchased AskBio in 2020.
biopharma_dive · 3mo ago

Data sources

ClinicalTrials.gov

last refreshed 38m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug

save

PER-001

Phase 2updated 3mo ago

by Perfuse Therapeutics Inc

Phase 2

community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying PER-001

phase2A Study of PER-001 in Participants With Diabetic Retinopathycompletedn=27
phase2A Study of PER-001 in Participants With Open-Angle Glaucomaactive not recruitingn=36

News(1)

Bayer to buy Perfuse for up to $2.45B, bolstering eye drug pipeline
Centered around a glaucoma therapy in mid-stage testing, the deal is Bayer’s first drug company acquisition in several years and potentially its largest since it purchased AskBio in 2020.
biopharma_dive · 3mo ago

Data sources

ClinicalTrials.gov

last refreshed 38m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

PER-001

all catalysts(0)

Trials studying PER-001

News(1)

Report a data issue

comments(0)

PER-001

all catalysts(0)

Trials studying PER-001

News(1)

Report a data issue

comments(0)